Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
12:00am, Thursday, 21'st May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
Charting a headline breakout attempt, S&P 500 nails major resistance (2,954)
05:02pm, Tuesday, 19'th May 2020
Technically speaking, the S&P 500 has once again nailed major resistance (2,954) — for the third time in as many weeks — placing a potentially consequential...
In The Midst Of Pandemic, Traders Pin Their Hopes On These Healthcare ETFs
01:38pm, Tuesday, 19'th May 2020In The Midst Of Pandemic, Traders Pin Their Hopes On These Healthcare ETFs
12:38pm, Tuesday, 19'th May 2020
Following months of mounting infection rates and rising economic uncertainty, the world is beginning to see brief glimmers of hope from the global COVID-19...
Coronavirus Vaccine Progress Accelerates
03:51pm, Thursday, 14'th May 2020
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
Catalent (CTLT) Stock Is Shining Bright During the Darkness of Coronavirus
04:25pm, Wednesday, 13'th May 2020
Bernzott Capital Advisors recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -32.76% (net) for the quarter, outperforming its benchmark,
Charting a grinding-higher May rally, S&P 500 approaches major resistance
04:40pm, Tuesday, 12'th May 2020
Technically speaking, the U.S. benchmarks’ grinding-higher recovery attempt remains in play, writes Michael Ashbaugh, though amid increasingly uneven price...
Is Catalent (CTLT) Stock a Good Buy During Covid-19 Uncertainty?
01:04pm, Tuesday, 12'th May 2020
Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their be
